Special Issue

Immunomarkers and Molecular Markers in the Diagnosis of Malignant Tumors

Message from the Guest Editors

A combined approach based on radiology and pathological examination currently represents the diagnostic gold standard of human neoplastic diseases. In relatively recent years, the introduction of new ancillary methods, including real-time polymerase chain reaction (rt-PCR), fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS), through which the molecular landscape of neoplasms can be studied, has improved diagnostic accuracy, Such methods have allowed the identification of new "entitydefining" genetic alterations, some of which have been included in the definition of many tumor entities. Soft tissue and central nervous system tumors represent emblematic examples of the application of molecular biology to human oncology. Accordingly, the identification of new immunomarkers along with molecular markers still represents one of the main goals of cancer scientific research. Based on this background, this Special Issue is devoted to the study of markers with both diagnostic and prognostic/predictive value in the field of human oncology.

Guest Editors

Prof. Dr. Gaetano Magro

Dr. Paolo G. Vigneri

Dr. Rosalba Parenti

Deadline for manuscript submissions

closed (31 October 2021)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.7
Indexed in PubMed



mdpi.com/si/69390

Diagnostics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.7
Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).

